Pivotal : Actualité Pivotal en direct - P1 | Bourse Reflex
Accueil > Tags > Pivotal

  • Toutes les actualités en rapport avec « Pivotal »

29/03 11:00 Pivotal - 2017 RESULTS: STRONG REVENUE GROWTH, PROFIT GENERATED IN SECOND HALF NEW STRATEGIC PLAN AND PLANNED SHARE ISSUE

27/02 08:15 Pivotal - FIGEAC AERO, TASNEE, AL SALAM AEROSPACE INDUSTRIES CO AND INDUSTRIAL CLUSTERS SIGN A COOPERATION AGREEMENT IN SAUDI ARABIA

15/09 08:55 Pivotal - Consolidated Turnover for Financial Year 2016-2017

16/06 13:15 Pivotal - SES-imagotag prepares for a partnership with BOE Technology Group to strengthen its global technological and industrial leadership

21/09 14:30 Pivotal - ELECTRO POWER SYSTEMS ACCELERATES DEVELOPMENT AND STRENGTHENS ITS MANAGEMENT TEAM TO SUPPORT GROWTH

26/07 11:00 Pivotal - FINANCIAL YEAR 2015/16 REVENUE

25/07 11:20 Pivotal - Artprice.com: Defying all forecasts... China upped 18%, dominated the global Art Market in the first half of 2016

11/07 18:00 Pivotal - CP Year End Results 2015-2016

21/12 08:00 Pivotal - Acquisition of Cast-Info - Aubay accelerates its development in Spain

17/12 08:00 Pivotal - SES wins the LSA Innovation Award

09/11 13:00 Pivotal - FIRST-QUARTER 2015/16 REVENUE

30/03 18:40 Pivotal - STORE ELECTRONIC SYSTEMS - 2014 annual results

02/03 19:00 Pivotal - 2014 Annual Results

17/02 11:00 Pivotal - Remarkable uptake in Quantum Genomics IPO* : EUR 11.2 million raised

29/07 09:00 Pivotal - Cancer Prevention Pharmaceuticals Receives Positive Scientific Advice From EMA for CPP-1X Phase III TRIAL in FAP

25/07 12:30 Pivotal - Raptor Pharmaceutical Meets Primary Endpoint in Its Phase 3 Clinical Trial of DR Cysteamine for Nephropathic Cystinosis

06/07 12:35 Pivotal - Raptor Pharmaceutical Receives Notices of Allowance for Two Key Patent Applications Protecting Its Cysteamine Portfolio

06/06 12:35 Pivotal - Raptor Pharmaceutical Provides Update on Phase 3 Clinical Trial of DR Cysteamine for the Potential Treatment of Nephropathic Cystinosis

18/04 08:55 Pivotal - IPSEN : partenariat avec Active Biotech en uro-oncologie

24/01 12:30 Pivotal - Raptor Pharmaceutical Completes Enrollment in Pivotal Phase 3 Clinical Trial of DR Cysteamine for the Potential Treatment of Nephropathic Cystinosis